The possible relationship between the AstraZeneca vaccine and cases of thrombi raises doubts about the Oxford University serum. The European Medicines Agency (EMA) has resumed this Tuesday the analysis on the relationship between vaccination and thrombosis and it will be this Wednesday, at 4:00 p.m., when it gives its conclusion on the evaluation of the safety of the AstraZeneca vaccine in these weeks.
Some doubts that were thrown precisely in a brief comment by one of the members of this body, creating this Tuesday again concern. “It is clear that there is an association [of thrombi] with the vaccine,” the head of EMA’s vaccine strategy, Marco Cavaleri , told Il Messaggero newspaper .
The phrase has caused official denials by the EMA and the European Commission, although not in the sense of denying that this relationship exists, but to clarify that there is still no conclusion of the new evaluation that is being carried out these days.
Cavaleri has once again raised the alarm voice by assuring that there is a link between the AstraZeneca vaccine and rare cases of thrombi, although he added that the EMA does not yet know “what causes this reaction.” “It is now increasingly difficult to say that there is no cause-and-effect relationship between vaccination with AstraZeneca and very rare cases of unusual blood clots associated with low platelet counts,” he said.
The EMA issued a statement hours later to clarify that it “has not yet reached a conclusion” on the relationship of the British vaccine and that the investigation “is still ongoing”. The organization will communicate its conclusions this afternoon at a press conference.
The European Commission, the institution on which the EMA depends, has also tried to blur Cavaleri’s words. His Health spokesperson, Stella Kyriakides , has indicated through social networks that the evaluation of AstraZeneca is not expected until this Wednesday at the last minute.
However, the possible link between this vaccine and the rare episodes of thrombosis, which have been observed particularly in women up to the age of 50, has returned concern to AstraZeneca, which for weeks led to suspend injections for a few days in several countries Europeans, including Spain. Here a 43-year-old woman died days after inoculating a dose, although the autopsy later revealed that it was due to an aneurysm unrelated to the puncture.
Immunization with this vaccine was resumed in Spain after a preliminary evaluation by the EMA in which it was unable to establish a link between AstraZeneca and the cases of thrombi, but neither did it rule it out completely, hence this week the evaluation on this has been resumed. issue, on which a worrying message was launched from within the EMA this Tuesday that there is a relationship between these two elements.
Meanwhile, some countries have begun to take precautions again. Interestingly, to protect the younger population from the possible adverse effects of AstraZeneca, unlike what happened when it began to be inoculated in Europe, in February. At the time, countries were more cautious about administering it to the older population and this led some to choose to inoculate it only up to 55 years of age.
This was the case in Spain, which first prescribed it for people between 18 and 55 years old and weeks later it was one of the last countries to raise the age to 65 years. Now, he is studying raising this threshold again and Dr. Fernando Simón indicated this Monday that “it is very likely that this decision will be made in a very short time.
“Every time the evidence is more solid” , that the vaccine is effective beyond 65 years, said the director of the CCAES, a day before doubts loom over the AstraZeneca vaccine.
Asked about the possible link between the Oxford University vaccine and thrombi, the President of the Government, Pedro Sánchez , admitted this Tuesday that it is “a concern for all citizens” and has also tried to detract from the words of the person in charge of the EMA vaccine, pointing out that the agency does not yet have “an official position.” Until then, he has conveyed “a message of confidence and tranquility” in a vaccine that since last week has been inoculated at high rates among the 55 to 65-year-old population.
Castilla y León stops vaccination until the EMA
For its part, Castilla y León have temporarily paralyzed and until the EMA is pronounced the vaccination with doses of Astrazeneca, due to the medical doubts it throws up.
For its part, the decision has had the reply of the Vice President of the Government, Carmen Calvo, who recalled that the Communities do not have the capacity to make this type of decision and summons him to the Interterritorial Council. “It is not foreseen that the communities use health or technical criteria to make political confrontation , despite their efforts,” he added.